Digestive Remedies in Indonesia: Market Overview & Outlook 2026-2030

Market Overview

Walk into any Indomaret near a Jakarta office tower at lunchtime and you will find a small rack by the till: strips of Promag, sachets of liquid antacid, Neo Entrostop, Antimo. Digestive remedies are among the most familiar medicines in Indonesian homes. They are cheap, sold almost everywhere and bought on the spot, often after a plate of sambal-heavy food, a third cup of coffee or a long bus ride home for Lebaran.

We estimate consumer spending on over-the-counter digestive remedies at about IDR 4.5 trillion in 2025, roughly USD 276 million at IDR 16,400 per dollar. That figure covers antacids, diarrhoeal remedies, laxatives, motion sickness remedies and digestive enzymes sold without a prescription through pharmacies, drugstores, minimarkets, small grocers and online. Value grew 5.0% a year between 2020 and 2025 in current prices, but growth slowed to 2.8% in 2025 as household budgets tightened.

The shape of that curve is worth a moment. The pandemic years were flat, because people travelled less and ate out less, and motion sickness remedies in particular collapsed in 2021. Then 2022 and 2023 were the strongest years in the series, with growth of X.X% and X.X%, as travel, eating out and Ramadan gatherings returned. Since then the market has settled back into a steadier rhythm. This is a need-driven category: it rarely booms, but it rarely shrinks either.

Per person, Indonesians spend only about IDR XX,XXX a year on these products, less than a dollar. That low figure says less about need than about price: a strip of antacid tablets costs about as much as a cup of street coffee. The market is built on volume, frequency and reach rather than on high ticket prices, which is why distribution matters so much in what follows.

Why Indonesians Reach for Digestive Remedies

Several everyday habits keep stomach complaints common. Indonesian cooking is often spicy and oily. Office workers skip breakfast, eat late and drink a lot of coffee. Commutes are long and stressful. Street food is part of daily life, and hygiene standards vary. Euromonitor's analysts point to the same mix of spicy food, irregular meals, stress-related gastritis and acid reflux as the main reasons demand has kept rising.

The most important number in that table for the industry is self-medication. According to BPS data reported by Kontan, XX% of Indonesians who fell ill in 2024 treated themselves, down slightly from peaks above XX% in 2021 and 2022. For a stomach ache, a bout of diarrhoea or a night of heartburn, almost nobody goes to a doctor first. They go to the pharmacy, the minimarket or the warung, and they ask for a brand they know.

Two longer-term shifts add to this. The population is ageing: people aged 60 and over made up XX.XX% of Indonesia's XXX.XX million people in 2025, according to the SUPAS survey, crossing the XX% threshold that demographers use to define an ageing society. Older adults suffer more from constipation and chronic acidity. And Indonesians travel more. The Ministry of Transportation expected XXX.X million people to travel during Lebaran 2026, and foreign tourist arrivals reached XX.XX million in 2025, the highest in six years. Every mudik season lifts sales of travel sickness tablets and antacids.

Some forces pull the other way. Post-pandemic hygiene habits, such as regular handwashing and more attention to food safety, reduce some diarrhoea episodes. Probiotic drinks and supplements, which we covered in our report on the dietary supplements industry, take part of the gut-health need outside this category. And weak purchasing power, the theme of our study on Indonesian purchasing power, makes some households delay purchases or switch to cheaper generics and home remedies.

Categories: Antacids, Diarrhoeal, Laxatives and Travel Sickness

Antacids are the heart of the market. They treat heartburn, the burning pain under the ribs that Indonesians call sakit ulu hati, bloating and acid reflux, and they account for almost half of all spending. Diarrhoeal remedies come second at about a third, and they are split between synthetic products such as attapulgite tablets and herbal products made from guava leaf, turmeric and other plant extracts. Laxatives, motion sickness remedies and a small, shrinking category of digestive enzymes make up the rest.

The mix is shifting slowly toward antacids. Their share rose from XX.X% in 2020 to XX.X% in 2025, because acidity and reflux are chronic and recurring. Someone who suffers heartburn after spicy food buys antacids again and again; someone who catches a stomach bug buys a diarrhoea remedy once. Digestive enzymes are the only category in long-term decline, losing out both to antacids and to probiotic products sold as supplements.

Motion sickness remedies tell the travel story most clearly. Sales almost halved in value terms in 2021, when travel was restricted, and then rebounded strongly as Indonesians returned to the roads and ferries. Paediatric travel sickness syrups for children, a tiny niche, have been the fastest-growing product group in the whole market since 2020. Which categories will grow fastest to 2030 is a question the full report answers with category-level forecasts.

Formats, Herbal Claims and the Modern Consumer

How people buy digestive remedies is changing faster than what they buy. Convenience is winning over price per dose. Kalbe's 7 ml liquid sachet of Promag is a good example: it costs more per millilitre than a bottle of suspension, but office workers like it because they can carry it and take it without water. Chewable tablets, single-dose sachets and children's syrups are all growing faster than classic tablets and bottles.

Herbal remedies are no longer a niche for the older generation. Diapet, a standardised herbal medicine made by Soho, is the second-largest digestive brand in the country. In November 2024 Kalbe launched Promag Herbal, made with honey, turmeric and licorice, at Jakarta Coffee Week with world barista champion Mikael Jasin. The idea, as reported by Kontan, is to position it as something coffee drinkers take before their cup to protect the stomach, and Kalbe said it planned to work with more than 10,000 coffee shops. Given how central coffee has become to urban life, as our coffee market report shows, that is a clever new occasion for an old brand.

Younger buyers also ask for sugar-free, gentle and natural products, and they read reviews and follow influencers before buying. Herbal products already hold about a XX% share of value by our estimate, and their share is rising. How herbal, liquid and probiotic formats will reshape the mix is one of the questions the full report explores.

Where Digestive Remedies Are Sold

Pharmacies and licensed drugstores are the biggest channel. Indonesia had 31,995 licensed pharmacies and 8,559 drugstores in 2023, according to the Ministry of Health's Health Profile reported by Databoks, and chains such as Kimia Farma, K-24, Century, Guardian and Watsons give consumers pharmacist advice and a wide range. Minimarkets come next. Indomaret and Alfamart put the leading green-circle brands right next to the till, which suits a product people buy on impulse when the pain starts. Small grocers sell single strips in villages where there is no pharmacy at all.

Indonesia's geography shapes the channel picture too. Java, home to XX.XX% of the population, has dense pharmacy networks and thousands of minimarkets within walking distance of most homes. In Sumatra, Kalimantan, Sulawesi and the eastern islands, distances are longer and the small grocer is often the only shop nearby, so a brand's reach depends on wholesalers and distributors who can serve remote villages profitably. This is where the integrated groups, with their own distribution arms, have a real edge: Kalbe works through Enseval and Soho through Parit Padang, and both also carry other companies' brands.

Online sales through Tokopedia, Shopee and Halodoc jumped during the pandemic and fell back in 2025, but they remain well above pre-pandemic levels. Brands now run official stores, sell bundles during flash sales and use teleconsultation to steer buyers to specific products. The growth of minimarket chains, which we analysed in our report on convenience retailers in Indonesia, has steadily widened the reach of over-the-counter brands beyond pharmacies.

Regulation: BPOM Classes, Herbal Rules and Halal Deadlines

Every digestive remedy sold in Indonesia needs a marketing authorisation from BPOM, the food and drug authority. The class printed on the pack decides where it can be sold. Free-sale medicines, marked with a green circle, can be sold anywhere from pharmacies to minimarkets. Limited free-sale medicines, marked with a blue circle, are restricted to pharmacies and licensed drugstores. Prescription medicines such as proton pump inhibitors carry a red K and sit outside this market. Most leading antacids and diarrhoea tablets are green-circle products, which is what lets them reach the minimarket counter.

The halal schedule is the rule to watch. Government Regulation 40/2026 moved the deadline for natural medicines, quasi drugs and supplements from October 2026 to 17 October 2028, while the deadline for free-sale and limited free-sale medicines stays at 17 October 2029. Large local makers have been preparing for years. For importers and small herbal makers, certifying every ingredient and production line is a real cost. In May 2026 BPOM also signalled tighter oversight of medicines sold outside pharmacies, including in minimarkets and supermarkets.

For anyone thinking of entering the market, the practical lesson is that regulation rewards patience. Registering a new product, preparing halal documentation and getting advertising approved all take time, and a herbal product that wants to make stronger claims needs pre-clinical or clinical evidence to move from jamu to standardised herbal medicine or fitofarmaka. Pricing, by contrast, is free: there are no price controls on branded over-the-counter digestive remedies, and the e-catalogue price rules that shape the prescription drug business apply only to medicines bought for the national health insurance scheme.

Competitive Landscape

This is one of the most concentrated consumer health markets in Indonesia. Kalbe Farma, the country's largest listed pharmaceutical group, leads with Promag and Neo Entrostop. Soho, with Diapet and Laxing, is second. Mylanta, owned by Kenvue until Kimberly-Clark completed its USD XX.X billion acquisition on 2 November 2026, is third. Together these three hold almost four-fifths of retail value by our estimate.

Shares move slowly in a market like this, but they do move. Kalbe's share has drifted down from the high forties at the start of the decade, while Mylanta gained ground with steady advertising for double-action relief of acid and gas. Soho has held its position thanks to Diapet's herbal positioning and influencer marketing aimed at younger buyers. Phapros has benefited from the travel rebound through Antimo, which owns the travel sickness category almost alone.

A pattern stands out: each symptom has one dominant brand. Promag owns the stomach, Diapet and Neo Entrostop share diarrhoea, Antimo owns travel. Decades of television advertising and distribution into tens of thousands of outlets make these positions hard to attack head-on. Challengers that succeed usually do so by owning a new need state or format rather than by competing on price. How the shares have moved since 2021, and which brands are gaining in each category, is covered in detail in the full report.

Key Players in Brief

The listed results show a healthy industry. Kalbe's consumer health division, which includes Promag alongside many other brands, sold IDR X.XX trillion in 2025. Soho grew profit by almost XX% and, in February 2026, won shareholder approval to turn its distributor Parit Padang into a broader health-tech and logistics platform. Phapros, part of the state-owned Bio Farma group, turned a loss of IDR XXX.X billion in 2024 into a profit, with over-the-counter sales led by Antimo growing fastest.

Global ownership is also in flux. Sanofi completed the sale of a controlling XX% stake in its consumer health business Opella, owner of Dulcolax and Polysilane, to CD&R in 2025, and Kenvue, owner of Mylanta and Microlax, is now part of Kimberly-Clark. Two of the top seven brands in Indonesia therefore have new parents. New owners often review local partners and marketing budgets, which could open doors for challengers or bring fresh investment to the brands. For a regional view of the drug industry, see our piece on pharmaceutical industry dynamics in Southeast Asia.

What This Means for Companies and Investors

This article describes the market as it stands today. The full report adds a Porter's Five Forces assessment, a shelf price build-up showing where each rupiah goes, business models across the value chain, seven mega trends, five company profiles and bear, base and bull forecasts to 2030 by category. You may also be interested in our recent reports on the fragrances industry and the cigarettes industry.

Key Questions Answered in the Full Report

Digestive Remedies in Indonesia Executive Summary

The three slides below summarise the full report. The complete 40-slide version, with the outlook to 2030, value chain, regulation analysis and company profiles, is available on Gumroad.

What the Full Report Includes